
Ismail Shehada
Ismail Shehada is the Chief Executive Officer of Tabuk Pharmaceuticals, bringing distinguished career over two decades of leadership at the forefront of the pharmaceutical industry. Known for scaling businesses in complex, competitive markets, he leads Tabuk’s strategic transformation, driving growth, operational efficiency, and long-term value creation across the region. His leadership combines deep market expertise with a relentless focus on execution,
culture, and performance.
Ismail previously held the position of Chief Executive Officer (CEO) of the Pharma sector within the Saudi Chemical Holding Group (SCCH). His leadership extends to roles as chairman and board director of the Care Supply Chain, a joint venture with a prestigious German company. Also, Ismail made significant contributions as the Country President for the Gulf Cooperation Council & Pakistan cluster at AstraZeneca, and as the Country Manager for Saudi Arabia at GlaxoSmithKline (GSK).
Ismail's impact on the Saudi Pharmaceutical industry is evident through his leadership in the private sector sub-committee at the National Committee for Pharmaceutical Industries (NCPI), and an Advisory Board Member of the Arab Pharma Manufacturers' Expo as well as being a former Vice Chairman of the Research-Based Pharmaceutical Companies (RPCC) . He has played a pivotal role in advocacy projects and shaping health policy issues in Saudi Arabia.
Recognized for his leadership and contributions to healthcare, Ismail has been honored in Forbes' list of Top Healthcare Leaders in the Middle East for 2023, named among the Top 100 Health Leaders in 2019, and celebrated as the best country president in the international region by AstraZeneca in 2018.
Academically, Ismail holds a BSc in Pharmacy from the Applied Science University, an Executive Master's degree in Senior Leadership Development from Hult International Business School, an advanced sales execution degree from ESCP Europe Business School, and a master class in oncology from GUSTAVE ROUSSY in Paris.